American Academy of Asthma, Allergy and Immunology (AAAAI)

BioCryst will attend the 2026 American Academy of Asthma, Allergy and Immunology (AAAAI) from Feb 27 – Mar 2, 2026.

  • Real-World Attack Rate Reductions After Berotralstat Initiation Among Patients with Hereditary Angioedema with Normal C1-Inhibitor Stratified by Prior Long-Term Prophylaxis
    AAAAI | 2026 | HAE
  • Impact of Berotralstat on Hereditary Angioedema Attack Rates in Patients with C1-Inhibitor Deficiency: Real-World Evidence Stratified by Prior Long-Term Prophylaxis
    AAAAI | 2026 | HAE
  • Reductions in Healthcare Resource Utilization Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency Following the Initiation of Berotralstat
    AAAAI | 2026 | HAE
  • Medication Routines Among Patients With Hereditary Angioedema
    AAAAI | 2026 | HAE
  • Oral Berotralstat Reduces the Rate of Moderate and Severe Attacks and Percentage of Days with HAE Symptoms Over 48 Weeks in Children Aged 2 to Less Than 12 Years: Interim Data from APeX-P
    AAAAI | 2026 | HAE

Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?

Have questions about our company?